Please login to the form below

Not currently logged in
Email:
Password:

SMA

This page shows the latest SMA news and features for those working in and with pharma, biotech and healthcare.

Novartis buys gene therapy firm AveXis for $8.7bn

Novartis buys gene therapy firm AveXis for $8.7bn

Last year, Biogen secured approval for the first drug treatment for SMA, a progressive, debilitating muscle-wasting disease that affects about 23, 500 patients worldwide. ... Only around 8% of SMA patients from a matched, historic cohort were still alive

Latest news

  • NICE finally starts review of Biogen’s Spinraza for SMA NICE finally starts review of Biogen’s Spinraza for SMA

    NICE finally starts review of Biogen’ s Spinraza for SMA. Will evaluate the treatment based on its Single Technology Appraisal process. ... In trials, Spinraza has been show to improve survival in infants with SMA and reduce the chances that they go on

  • Biogen wins European spinal muscular atrophy first Biogen wins European spinal muscular atrophy first

    Biogen wins European spinal muscular atrophy first. Spinraza wins accelerated approval to treat patients with the most common form of SMA. ... mechanical ventilation procedures, and showing that its benefits extend to children with less-severe,

  • CHMP backs two rare disease therapies at April meeting CHMP backs two rare disease therapies at April meeting

    Biogen closed in on EU approval of its spinal muscular atrophy (SMA) treatment Spinraza (nusinersen) in Europe, having already picked up a US approval for the highly-priced drug as 2016

  • Biogen proffers new data to support high-priced Spinraza Biogen proffers new data to support high-priced Spinraza

    Biogen proffers new data to support high-priced Spinraza. Trial demonstrates statistically-significant risk reduction in paediatric SMA for potential blockbuster drug. ... New data from a pivotal trial of Biogen's Spinraza for infants with spinal

  • FDA approves Biogen's Spinraza for spinal muscular atrophy FDA approves Biogen's Spinraza for spinal muscular atrophy

    The usual end-year flurry of FDA approvals didn't happen in 2016, although Biogen got the okay for its spinal muscular atrophy (SMA) drug Spinraza as the year drew to ... Spinraza (nusinersen) became the first drug to be approved in the US to treat

More from news
Approximately 5 fully matching, plus 14 partially matching documents found.

Latest Intelligence

  • Deal Watch July 2016 Deal Watch July 2016

    In 2014 the partners expanded the agreement for CK-2127107 to include some neuromuscular indications, such as Spinal Muscular Atrophy (SMA).

  • Pharma deals during January 2013 Pharma deals during January 2013

    Repligen announced the signature of an exclusive worldwide licensing agreement with Pfizer to advance Repligen's spinal muscular atrophy (SMA) programme. ... SMA is an orphan neurodegenerative genetic disease that presents early in life.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wordbird

Wordbird is a healthcare communications agency with creative, compelling copy at its heart....

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics